It is concluded that EAM-2201 has the potential to set off in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and it is evaluated in pooled human liver microsomes. In vitro benefits indicate that AM-2201 ought to be examined for possible pharmacokinetic drug interactions in https://peterf959kzn1.national-wiki.com/user